Guggenheim Reiterates “Buy” Rating for Teladoc Health (NYSE:TDOC)

Teladoc Health (NYSE:TDOC)‘s stock had its “buy” rating reissued by Guggenheim in a research note issued on Tuesday, The Fly reports. They presently have a $110.00 price objective on the health services provider’s stock, up from their prior price objective of $90.00. Guggenheim’s target price points to a potential upside of 17.02% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. Wells Fargo & Co raised their price target on shares of Teladoc Health from $77.00 to $95.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 8th. SunTrust Banks restated a “hold” rating and set a $80.00 price target on shares of Teladoc Health in a research note on Monday, December 2nd. Royal Bank of Canada started coverage on shares of Teladoc Health in a research note on Wednesday, November 27th. They issued an “outperform” rating and a $100.00 price objective for the company. Bank of America lowered shares of Teladoc Health from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $82.00 to $90.00 in a research note on Thursday, January 9th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Teladoc Health from $82.00 to $83.00 and gave the company an “overweight” rating in a research note on Thursday, September 19th. Nine analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $87.71.

Shares of TDOC stock opened at $94.00 on Tuesday. The company has a 50 day moving average of $82.71 and a 200-day moving average of $72.24. The company has a quick ratio of 6.55, a current ratio of 6.55 and a debt-to-equity ratio of 0.44. Teladoc Health has a 12-month low of $48.57 and a 12-month high of $98.97. The firm has a market cap of $6.80 billion, a P/E ratio of -65.28 and a beta of 1.38.

Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, October 30th. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.12. Teladoc Health had a negative net margin of 20.15% and a negative return on equity of 11.23%. The company had revenue of $137.96 million during the quarter, compared to analyst estimates of $136.46 million. During the same quarter last year, the business posted ($0.34) EPS. Teladoc Health’s quarterly revenue was up 24.3% compared to the same quarter last year. As a group, equities analysts expect that Teladoc Health will post -1.55 EPS for the current year.

In other news, insider Adam C. Vandervoort sold 3,525 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $79.12, for a total transaction of $278,898.00. Following the completion of the transaction, the insider now directly owns 1,114 shares in the company, valued at approximately $88,139.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Adam C. Vandervoort sold 50,955 shares of the business’s stock in a transaction on Thursday, October 31st. The shares were sold at an average price of $75.00, for a total transaction of $3,821,625.00. Following the transaction, the insider now owns 9,769 shares of the company’s stock, valued at $732,675. The disclosure for this sale can be found here. Insiders sold a total of 68,099 shares of company stock valued at $5,151,311 over the last quarter. 3.14% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in TDOC. Nuveen Asset Management LLC grew its position in shares of Teladoc Health by 2,939.6% during the 2nd quarter. Nuveen Asset Management LLC now owns 608,824 shares of the health services provider’s stock valued at $40,432,000 after purchasing an additional 588,794 shares in the last quarter. Waddell & Reed Financial Inc. grew its position in shares of Teladoc Health by 32.5% during the 2nd quarter. Waddell & Reed Financial Inc. now owns 2,335,837 shares of the health services provider’s stock valued at $155,123,000 after purchasing an additional 572,388 shares in the last quarter. Macquarie Group Ltd. grew its position in shares of Teladoc Health by 59.9% during the 2nd quarter. Macquarie Group Ltd. now owns 1,490,807 shares of the health services provider’s stock valued at $99,005,000 after purchasing an additional 558,650 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of Teladoc Health by 114.7% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,041,327 shares of the health services provider’s stock valued at $70,519,000 after purchasing an additional 556,269 shares in the last quarter. Finally, Nikko Asset Management Americas Inc. grew its position in shares of Teladoc Health by 44.3% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 1,041,327 shares of the health services provider’s stock valued at $70,519,000 after purchasing an additional 319,556 shares in the last quarter.

Teladoc Health Company Profile

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Featured Article: Accumulation/Distribution

The Fly

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.